Search results
Showing 16 to 30 of 46 results for cardiomyopathy
Extracorporeal membrane oxygenation (ECMO) in postneonatal children (HTG17)
Evidence-based recommendations on extracorporeal membrane oxygenation in postneonatal children. This involves connecting the child's internal circulation to an external blood pump and artificial lung.
View recommendations for HTG17Show all sections
Sections for HTG17
Evidence-based recommendations on non-surgical reduction of myocardial septum. This involves inserting a catheter into the femoral artery and passing it up into the heart under X-ray control.
View recommendations for HTG18Show all sections
Sections for HTG18
Permanent His-bundle pacemaker implantation for treating heart failure (HTG579)
Evidence-based recommendations on permanent His-bundle pacemaker implantation for treating heart failure. This involves attaching a wire connected to a pacemaker to the heart’s electrical conduction pathway (through a vein).
View recommendations for HTG579Show all sections
Percutaneous mitral valve leaflet repair for mitral regurgitation (HTG513)
Evidence-based recommendations on percutaneous mitral valve leaflet repair for mitral regurgitation in adults. This involves attaching a clip to the leaflets of the mitral valve.
View recommendations for HTG513Show all sections
Intrapartum care: existing medical conditions and obstetric complications (QS192)
This quality standard covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. It also covers women who have had no antenatal care. It describes high-quality care in priority areas for improvement. It does not cover the antenatal and postnatal care of pregnant women with mental health conditions, hypertension in pregnancy, diabetes in pregnancy or the organisation of care for pregnant women with complex social factors.
View quality statements for QS192Show all sections
Sections for QS192
- Quality statements
- Quality statement 1: Involving women in care planning
- Quality statement 2: Composition of the multidisciplinary team
- Quality statement 3: Heart disease – risk assessment
- Quality statement 4: Assessment and antibiotic treatment for suspected sepsis
- Quality statement 5: Women with no antenatal care
- Update information
- About this quality standard
Transient loss of consciousness ('blackouts') in over 16s (CG109)
This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.
Diabetes in pregnancy: management from preconception to the postnatal period (NG3)
This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.
Our forward view highlights the topics we will prioritise in the coming year.
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.
Outside interests of the NICE board
Past technology appraisal appeals and decisions
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)
This guidance has been updated and replaced by NICE technology appraisal guidance 984.
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]
In development Reference number: GID-TA11664 Expected publication date: TBC